Pharvaris PHVS 深 沪
等待开盘 05-18 09:30:00 美东时间
30.40
-0.300
-0.98%
华盛通- 最 高30.44
- 今 开30.34
- 成交量 44.42万股
- 最 低 29.36
- 昨 收 30.70
- 总市值 19.88亿
- 52周最高 33.33
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 15.46
- 委 比 57.47%
- 总股本 6540.78万
- 历史最高 42.86
- 量 比 0.91
- 振 幅 3.52%
- 历史最低 1.77
- 每 手 1
- 风险率 3.86%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
Citizens Maintains Market Outperform on Pharvaris, Lowers Price Target to $74
Citizens analyst Jonathan Wolleben maintains Pharvaris (NASDAQ:PHVS) with a Market Outperform and lowers the price target from $75 to $74.
05-13 22:28
Pharvaris Q1 EPS $(0.69) Beats $(0.77) Estimate
Pharvaris (NASDAQ:PHVS) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(0.77) by 10.39 percent. This is a 22.47 percent increase over losses of $(0.89) per share from the
05-13 05:19
Pharvaris Prices Underwritten Offering Of 3,874,664 Shares At $29.68 Per Share
All shares in the offering are to be sold by Pharvaris. In addition, Pharvaris has granted the underwriters a 30-day option to purchase up to an additional 581,199 ordinary shares at the public offering price, less
05-08 18:03
Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares
Pharvaris N.V. announced the pricing of an underwritten offering of 3,874,664 ordinary shares at $29.68 per share, expected to raise approximately $115 million. The company, focused on developing oral bradykinin B2 receptor antagonists for treating bradykinin-mediated diseases like HAE and AAE-C1INH, is preparing for regulatory approvals and advancing its Phase 3 studies for deucrictibant.
05-08 10:00
Pharvaris Presents Data Evaluating Safety Margins Of Administration Of Deucrictibant IR Capsule In Combination With Deucrictibant XR Tablet At CIIC Spring 2026 Conference
Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary
04-20 18:53
美股大行评级 | 小摩上调Lumentum控股目标价从565美元升至950美元；大小摩齐上调美国铝业目标价
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从13美元升至13.5美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8.25美元升至9美元
04-10 18:27
美股大行评级 | 高盛首予PayPay“买入”评级；神经分泌生物科学获花旗等多家机构上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从13美元升至20美元；韦德布什：维持FuboTV"跑赢大市"评级，目标价从3.5美元升至24美元
04-08 18:35
美股大行评级 | 目标价31美元，潜在涨幅64%！多家大行首予PayPay"买入"评级； 大摩上调希捷科技目标价从468美元升至582美元
今日重点评级关注：Canaccord Genuity：维持Taysha Gene Therapies"买入"评级，目标价从14美元升至17美元；Guggenheim：维持天演药业"买入"评级，目标价从9美元升至10美元
04-07 11:53
Pharvaris Moves Closer To New Preventive Treatment For Rare Swelling Disorder
Pharvaris enrolled deucrictibant XR for HAE in CHAPTER 3. Positive results could lend 30% upside to the stock, says Guggenheim analyst.
04-06 23:13
